Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report
Alpelisib plus fulvestrant is a valid second or advanced line of treatment for patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who harbor an activating PIK3CA mutation. The well-known side effects of alpelisib are hyperglycemia, rash, and diarrhea. Herein, we rep...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1255832/full |
| _version_ | 1797645410732343296 |
|---|---|
| author | Maayan Geller Hinich Adham Hijab Adham Hijab |
| author_facet | Maayan Geller Hinich Adham Hijab Adham Hijab |
| author_sort | Maayan Geller Hinich |
| collection | DOAJ |
| description | Alpelisib plus fulvestrant is a valid second or advanced line of treatment for patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who harbor an activating PIK3CA mutation. The well-known side effects of alpelisib are hyperglycemia, rash, and diarrhea. Herein, we report a case of a woman who developed diffuse depigmented macules on the face, arms and legs, three months after initiating alpelisib. Both clinical and histopathological findings were consistent with new-onset vitiligo. To our knowledge, this is the first case described in literature which suggests a causal relationship between alpelisib and irreversible dermatological adverse effect. |
| first_indexed | 2024-03-11T14:45:57Z |
| format | Article |
| id | doaj.art-1092b2bf5daa45289db085507df4371d |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-11T14:45:57Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-1092b2bf5daa45289db085507df4371d2023-10-30T11:02:41ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-10-011310.3389/fonc.2023.12558321255832Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case reportMaayan Geller Hinich0Adham Hijab1Adham Hijab2Oncology Division, Ziv Medical Centre, Safed, IsraelOncology Division, Ziv Medical Centre, Safed, IsraelRadiotherapy Unit, Ziv Medical Centre, Safed, IsraelAlpelisib plus fulvestrant is a valid second or advanced line of treatment for patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who harbor an activating PIK3CA mutation. The well-known side effects of alpelisib are hyperglycemia, rash, and diarrhea. Herein, we report a case of a woman who developed diffuse depigmented macules on the face, arms and legs, three months after initiating alpelisib. Both clinical and histopathological findings were consistent with new-onset vitiligo. To our knowledge, this is the first case described in literature which suggests a causal relationship between alpelisib and irreversible dermatological adverse effect.https://www.frontiersin.org/articles/10.3389/fonc.2023.1255832/fullvitiligoalpelisibbreast cancerPIK3CAskin adverse effects |
| spellingShingle | Maayan Geller Hinich Adham Hijab Adham Hijab Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report Frontiers in Oncology vitiligo alpelisib breast cancer PIK3CA skin adverse effects |
| title | Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report |
| title_full | Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report |
| title_fullStr | Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report |
| title_full_unstemmed | Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report |
| title_short | Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report |
| title_sort | acrofacial vitiligo secondary to pi3kca inhibitor alpelisib case report |
| topic | vitiligo alpelisib breast cancer PIK3CA skin adverse effects |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1255832/full |
| work_keys_str_mv | AT maayangellerhinich acrofacialvitiligosecondarytopi3kcainhibitoralpelisibcasereport AT adhamhijab acrofacialvitiligosecondarytopi3kcainhibitoralpelisibcasereport AT adhamhijab acrofacialvitiligosecondarytopi3kcainhibitoralpelisibcasereport |